Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE This study shows the benefits of pallidal DBS for the dystonia of PKAN patients. 15852393 2005
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE The present study confirms the effectiveness of pallidal DBS in a new family with hereditary primary segmental and generalized dystonia. 19890997 2009
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 GeneticVariation phenotype BEFREE Some of the rarer types of dystonia that have also been treated with DBS are also described. 20083014 2009
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE There was a significant improvement of dystonia with GPi-DBS (69 % improvement in Burke-Fahn-Marsden score, p < 0.0001). 24178706 2014
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE Clinically, no generalization of dystonia was observed after onset and DBS lead to an excellent motor outcome in two cases. 26725140 2016
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE As the course of disease duration as well as the age at operation seem to correlate with DBS outcome in patients with dystonia, DBS at an early stage of development might be beneficial for some of these patients. 27289260 2017
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE GPi-DBS should be considered to ameliorate the invalidating dystonia in these patients. 27862284 2017
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE DBS effects on dystonia severity were variable but overall marginally effective, with a mean improvement of 7.9% (p = 0.39) at 1-year follow-up and 16.7% (p = 0.46) at last follow-up (mean 47.3 ± 19.9 months after surgery). 27743838 2017
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE To assess safety and tolerability of square biphasic DBS in dystonia patients. 28195407 2017
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE GPi DBS is an effective and safe treatment in most patients with dystonia. 28972096 2017
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE Our results showed that bilateral GPi DBS in craniocervical dystonia is effective and safe. 29246604 2017
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE We here investigated causes of insufficient response to GPi-DBS in isolated dystonia in a cross-sectional study. 28690015 2017
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE Pallidal DBS for dystonia in the age of personalized medicine. 28964627 2017
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE We describe lessons learnt from available dystonia studies and discuss/propose ways to measure DBS and other dystonia-related intervention outcomes. 27707656 2017
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE Fifty-four subjects with dystonia and DBS for more than 5 years were contacted via social media and were offered to complete a quality-of-life survey comparing current-day life and life prior to DBS. 30153389 2018
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE All these results support the multilevel impact of effective DBS on the motor networks in dystonia and suggest potential biomarkers of responsiveness to this treatment. 30464181 2018
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE DBS has been trialed to treat related movement disorders, particularly dystonia. 30633810 2019
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE Interestingly, DBS for PD can cause dystonia such as blepharospasm and bilateral pallidal DBS for dystonia can result in features of parkinsonism. 31078682 2019
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE Pallidal deep-brain stimulation of the internal globus pallidus (GPi-DBS) is an effective treatment for dystonia. 30623266 2019
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE We aimed to assess whether the thalamic ventral intermediate nucleus (Vim) might be an alternative DBS target in dystonia-choreoathetosis. 30718219 2019
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE Peak low frequency IMC functioned as biomarker for GPi-DBS efficacy, and partly correlated with dystonia severity. 31207566 2019
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE To objectively investigate the impact of GPi-DBS on patients with dystonia on speech fluency, intelligibility, and key aspects of hyperkinetic and hypokinetic dysarthria. 29576500 2019
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE A dramatic and long-lasting response to DBS is characteristic of DYT-KMT2B dystonia. 31216378 2019